Variable	N	HR	95%CI	Disease Free Survival	HR	95%CI	Overall Survival
Sex (Male)	102	1.277	0.756 - 2.157		1.094	0.603 - 1.984	
Sex (Female)	51	1.063	0.497 - 2.272		1.214	0.486 - 3.032	
Age (<65)	117	1.354	0.828 - 2.213		1.234	0.715 - 2.131	
Age (≥65)	36	0.767	0.287 - 2.049		0.568	0.151 - 2.131	
PS (ECOG0)	98	1.201	0.686 - 2.103		1.286	0.668 - 2.477	
PS (ECOG1)	55	1.144	0.581 - 2.253		0.822	0.386 - 1.753	
Stage IIIA	19	1.257	0.314 - 5.035		0.836	0.139 - 5.018	
Stage IIIB	69	0.620	0.298 - 1.288		0.581	0.253 - 1.331	
Stage IIIC	65	2.018	1.108 - 3.675		1.894	0.953 - 3.765	
T stage (pT2-3)	44	0.743	0.331 - 1.670		0.551	0.196 - 1.547	
T stage (pT4)	109	1.507	0.888 - 2.561		1.450	0.794 - 2.647	
N stage (pN0-2)	54	1.618	0.587 - 4.458		1.916	0.575 - 6.388	
N stage (pN3)	99	1.208	0.748 - 1.951		1.052	0.605- 1.829	
All	153	1.201	0.781 - 1.848		1.081	0.659 - 1.772	

Disease Free Survival: 0.1 — 1 — 10 · DS Better / SP Better

Overall Survival: 0.1 — 1 — 10 · DS Better / SP Better

S3 Fig. Forest plots of subgroup analyses of disease free survival and overall sruvival. Hazard ratio (HR) are based on stratified proportional-hazards model. Horizontal bars represent 95% confidential interval (CI). S-1 plus cisplatin (SP) showed tendency for better benefit of disease free survival in stage IIIC subgroup, but no other subgroup showed any significant difference of survival benefit among docetaxel plus S-1 (DS) or SP chemotherapy group. ECOG, Eastern Cooperative Oncology Group, PS, performance status.